Fig. 2From: Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsImplementation workflow of the longitudinal and ensemble modelsBack to article page